Navigation Links
Use Anemia Drugs for Cancer Patients With Caution, Experts Say
Date:10/26/2010

TUESDAY, Oct. 26 (HealthDay News) -- Physicians need to use caution when giving a class of drugs called erythropoiesis-stimulating agents (ESAs) to cancer patients who have anemia caused by chemotherapy, according to new medical guidelines.

And with rare exceptions, ESAs should not be given to cancer patients who are not receiving chemotherapy, according to joint guidelines issued by the American Society of Hematology and the American Society of Clinical Oncology.

ESAs (marketed as Procrit, Epogen and Aranesp) stimulate the bone marrow to produce more red blood cells but are associated with shorter survival and increased risk of blood clots and tumor progression, the guidelines noted.

However, ESAs reduce the need for red blood cell transfusions, which carry a risk of serious infection and adverse reactions in the immune system.

The guidelines offer specific recommendations on the use of ESAs. Among them:

  • ESAs should not be given to cancer patients who are not receiving chemotherapy, except for those with myelodysplastic syndrome (MDS).
  • Doctors should discuss individual risks and benefits of ESAs and blood transfusion with patients before therapy. This shared decision-making is critical.

"This updated guideline offers clinicians the latest synthesis of the medical evidence surrounding the use of ESAs in patients with cancer, including appropriate cautions where evidence is lacking or where risks may outweigh the use of ESAs," guideline panel co-chair Dr. J. Douglas Rizzo, professor of medicine at the Medical College of Wisconsin, said in an American Society of Hematology news release.

"These guidelines touch on almost all aspects of the use of ESAs in patients with cancer and MDS, as well as secondary issues, such as the role of iron supplementation," Dr. Samuel Silver, a member of the ASH Committee on Practice and a professor of internal medicine at the University of Michigan, added in the news release.

The updated guidelines appear online Oct. 25 ahead of print in the Nov. 18 issue of Blood and the Nov. 20 issue of the Journal of Clinical Oncology.

More information

The U.S. Food and Drug Administration has more about ESAs.

-- Robert Preidt

SOURCE: American Society of Hematology, news release, Oct. 25, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Back Anemia Drugs for Kidney Patients
2. Anemia Drugs Could Pose Threat to Some Kidney Patients
3. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
4. OHSU joins forces with UO, Harvard to accelerate Fanconi anemia research
5. Anemia Drugs Hold Dangers for Kidney Patients
6. Anemia Harder to Treat in Black Children With Kidney Disease
7. Anemia tougher to tackle in black children with kidney disease
8. For Some on Dialysis, Anemia Drugs Pose Risks
9. FDA Tightens Controls on Anemia Drugs
10. FDA Calls for New Warnings on Some Prostate Cancer Drugs
11. Penn study gives hope for new class of Alzheimers disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Use Anemia Drugs for Cancer Patients With Caution, Experts Say 
(Date:2/8/2016)... ... ... Discover the Rocky Mountain region’s longest running and impressive garden and home show ... to see the most incredible gardens and home improvement experts that attend this amazing ... Center - 700 14th St. Denver CO, is an exciting event that Performance Mobility ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Inc., will be speaking on how healthcare companies can use newly released government ... the health of a population and intervene and capture the value they create ...
(Date:2/7/2016)... Metamora, Michigan (PRWEB) , ... February 07, 2016 ... ... pelvic organ prolapse with the latest techniques and the most minimally invasive approaches. ... pelvic organ prolapse, particularly after menopause. Other risk factors include surgery to the ...
(Date:2/6/2016)... ... February 06, 2016 , ... FOR INFORMATION: ... AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference is the ... perioperative nurses in attendance to study the latest evidence-based recommendations and resources ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... DIEGO , Feb. 8, 2016 /PRNewswire/--  Cell ... announced that advanced tissue-engineering services are now available ... a groundbreaking new three-dimensional (3D) bioprinting approach called ... 3D Bio Printer , a state-of-the-art robotic system ... has created a powerful pay-for-service bio-printing model that ...
(Date:2/8/2016)... , Feb. 8, 2016 ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ...
(Date:2/8/2016)... Pharma Inc. President and Chief Executive Officer Yoshihiko Hatanaka ... as president, Americas Operations, for Astellas US LLC, with responsibility ... America , effective April 1, 2016.  Robinson previously served ... the United States -- a role ... who is retiring in June 2016.  --> ...
Breaking Medicine Technology: